28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
In last two decades the growing life expectancy has spiralled the prevalence of neurogenerative disorder such as Dementia among elderly population posing a significant challenge to mental health globally. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Dementia, the most common subtype of which is Alzheimer’s disease, represents a significant global and social health challenge. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The results suggest a viable pathway for developing ML support tools to provide feedback on DDP compliance at an early design stage. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The global increase in the elderly population, which is expected to reach 2.1 billion by 2050, has highlighted the need for reliable monitoring systems to assist elderly individuals, especially those with dementia. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
While this process allows machine learning models to make more precise and reliable diagnoses, systems developed on the basis of Dr. Roman Poznanski's DOT (Dynamic Optimization of Thought) theory offer a new method in the diagnosis of neurological diseases. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Overall, AI has substantial potential to support more precise, person-centred care for older adults, but realising this promise will require multimorbidity-aware, transparent models, robust evaluation in diverse geriatric populations and governance frameworks that ensure fairness, privacy and meaningful human oversight. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer's disease (AD) is the most common type of dementia and represents a significant global health problem due to its profound impact on patients' quality of life and the heavy burden it places on health care. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
AbstractO_ST_ABSBackgroundC_ST_ABSGlucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter-2 (SGLT2) inhibitors are increasingly used for type 2 diabetes. 5 key findings →
Participants: 6,328 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
IntroductionFrontotemporal lobar degeneration (FTLD) is a devastating disease that commonly results in early onset dementia, yet its rarity and heterogeneity limit large-scale research and clinical trials. 2 key findings →
Design: longitudinal study Participants: 567 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Pain assessment remains challenging in clinical practice. 1 key finding →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Artificial intelligence can assist providers in a variety of patient care and intelligent health systems. 1 key finding →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source
A bstract Deep learning models for electroencephalography (EEG) pathology detection achieve competitive accuracy but offer limited interpretability. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer disease (AD) is a disorder of the nervous system that mostly impacts the brain cells and causes the slow destruction of the brain. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Patients with peripheral artery disease (PAD), chronic limb-threatening ischemia (CLTI), and/or diabetic foot ulcer (DFU) are at increased risk for limb loss and death. 3 key findings →
Participants: 178,995 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Neuroimaging studies that pool data across clinical sites often suffer from site effects — variability in imaging measures that arises from technical heterogeneity across sites as opposed to true biological signal. 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Open-source deep learning models promise scalable quantification of MRI-visible perivascular spaces (PVS), an emerging marker of glymphatic dysfunction in Alzheimer’s disease (AD). 4 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Subcortical brain alterations are a key feature of dementia disease progression. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Artificial-intelligence (AI) systems for Alzheimer’s disease (AD) increasingly use neuroimaging or spontaneous speech, but reported performance is difficult to interpret across studies because cohorts, endpoints, languages, preprocessing, and validation protocols differ. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Deep learning classifiers trained on structural magnetic resonance imaging (MRI) are increasingly proposed for early detection of Alzheimer’s disease (AD) and mild cognitive impairment (MCI), yet the pipelines that produce these models depend on shared datasets, pre-trained weights, and federated updates that an adversary can poison. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Digital medication-management tools for Alzheimer's disease (AD) typically record only whether a dose was taken, leaving the temporal and behavioral structure of adherence largely unused as a predictive signal. 2 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Recent research has revealed that linguistic features are effective digital markers for the early detection of Alzheimer’s disease (AD). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The MCI group had the most surprising findings—although they were cognitively similar to the control group, they were less physically active than the AD group and had the worst sleep efficiency. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer’s disease (AD) is increasing in prevalence, and early detection is essential for timely care. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →